- 1 Full Title: Risk factors for renal stone development in adults with primary hyperparathyroidism:
- 2 A protocol for a systematic review and meta-analysis 3
- 4 Short Title: Renal stone risk factors in primary hyperparathyroidism
- 5 6 Review team: Mohammad Jay¹, Sorina Andrei², Peter Hoang³, Hussein Samhat⁴, Roland Jones⁵,
- Rui Fu⁶, Lorraine Lipscombe^{1*}, Antoine Eskander^{7*†} 7
- 8 * Denotes co-senior authors
- 9

10 *Co-senior authors

11

14

21

22

23 24

25

26

30

- 12 Affiliations: 13
 - 1. Division of Endocrinology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
- 15 2. Institute of Health Policy, Management and Evaluation, Dalla Lana School of Public 16 Health, University of Toronto. Toronto, Ontario, Canada.
- 17 3. Division of Geriatrics, Department of Medicine, University of Toronto, Toronto, Ontario, 18 Canada.
- 19 4. Department of Epidemiology, Biostatistics and Occupational Health, McGill University, 20 Montreal, Quebec, Canada.
 - 5. Department of Psychiatry, University of Toronto. Toronto, Ontario, Canada.
 - 6. Departments of Community Health Sciences, Surgery & Oncology, Cumming School of Medicine, University of Calgary. Calgary, Alberta, Canada.
 - 7. Department of Otolaryngology, Head and Neck Surgery, Department of Surgery, University of Toronto, Toronto, Ontario, Canada.
- 27 *Corresponding author: Mohammad Jay. Address: Sunnybrook Health Sciences Centre, 2075 28 Bayview Avenue, M1-102, Toronto, ON, M4N 3M5. Phone: (416) 480-6705. Fax: (416) 29 480-5761. Email: Mohammad.jay@mail.utoronto.ca
- 31 Funding: No source of funding was used for this study.
- 32 **Competing interests**: The authors declare no conflict of interest.

33 34 35 36 Abstract word count: 267

- 37 Manuscript word count: 4516
- 38
- 39
- 40 41
- 42
- 43
- 44
- 45

46 Abstract

47 Background: Primary hyperparathyroidism (PHPT) is characterized by overactive parathyroid 48 glands. Renal stones (RS) are a common complication of PHPT and is associated with increased 49 morbidity. However, the risk factors for RS in PHPT are not well-established and the latest 50 international PHPT guideline highlights the need for further research into this area.

51 Objective: We aim to summarize and meta-analyze the existing evidence on prespecified risk
52 factors associated with RS in adults with PHPT.

53 Methods and Analysis: We will search MEDLINE, EMBASE, and Cochrane Central from 54 inception. Two independent reviewers will screen studies and include prospective/retrospective 55 cohort, case-control, and cross-sectional designs in adults (≥ 18 years) with PHPT. Randomized 56 trials, conference abstracts, case reports, and commentaries will be excluded. Two reviewers will 57 independently extract data on population characteristics, risk factors, RS outcomes, and assess 58 risk of bias using the Quality in Prognostic Studies tool. A random-effects model will be used to 59 pool odds ratios. We will separately pool adjusted (primary analyses) and unadjusted odds ratios 60 (secondary analyses) with their corresponding 95% confidence intervals. Certainty will be 61 evaluated with the Grading of Recommendations Assessment, Development, and Evaluation 62 framework. Heterogeneity will be assessed using the I² statistic and publication bias will be 63 evaluated with funnel plots.

Discussion: Early identification of patients with PHPT at high risk for RS can facilitate the implementation of preventive strategies and reduce morbidity. Furthermore, recognizing these risk factors can assist clinicians in prioritizing treatment for those at higher risk, ultimately improving patient outcomes.

68	Protocol	registration:	The	protocol	was	registered	in	PROSPERO	on	November	14,	2024
----	----------	---------------	-----	----------	-----	------------	----	----------	----	----------	-----	------

- 69 (registration ID: CRD42024608180).
- **Funding**: No source of financial funding was used.

71			
72			
73			
74			
75			
76			
77			
78			
79			
80			
81			
82			
83			
84			
85			
86			
87			
88			
89			
90			
91			
92			
93			
94			
95			
96			
97			
98			
99			
100			
101			
102			
103			
104			
105			
106			
107			
108			
109			

111 Heading: INTRODUCTION & OBJECTIVES

112 Sub-heading: 1. Introduction

113 Primary hyperparathyroidism (PHPT) is characterized by elevated serum parathyroid hormone 114 (PTH) levels and consequent disruption of calcium metabolism (1, 2). The resulting 115 hypercalcemia can lead to several serious complications, including renal stones (RS), renal 116 failure, and osteoporosis (3). PHPT affects roughly 600,000 Canadians (2, 3). An estimated 40% 117 of patients with PHPT develop RS, a complication associated with severe pain leading to 118 frequent emergency department (ED) visits, a 1.4-fold increased mortality risk, and a 2.3-fold 119 higher risk of renal failure (4, 5). In many countries, the direct costs of RS management and lost 120 work productivity is estimated to total billions of dollars annually (6, 7).

121 PHPT treatment guidelines recommend reserving curative treatment, parathyroidectomy, 122 for patients at high risk of complications, such as RS (8-10). Early identification of patients with 123 PHPT at high risk of developing RS has important implications for optimizing monitoring 124 schedules, implementing preventative strategies and prioritizing parathyroidectomy (11-15). 125 Although multiple systematic reviews have examined RS risk factors in the general population, 126 their applicability to PHPT is uncertain, given that this population experiences disease-specific 127 changes in calcium metabolism (16-19). For instance, older age, male sex, and hypercalciuria are 128 commonly recognized risk factors in broader RS literature, but whether these factors have similar 129 associations in individuals with PHPT is unclear (18). Equally important is whether PHPT-130 specific drivers of incident or recurrent RS-such as excessively high serum calcium or PTH-131 operate independently or in conjunction with known risk factors from the general population (16, 132 20, 21). Most evidence to date has focused on the hallmark biochemical features of PHPT (i.e., 133 serum calcium and PTH levels) and patient demographic characteristics such as age and sex (16,

20, 21). However, findings across studies have been inconsistent (21); while some studies
suggested that RS risk is associated with younger age, higher serum calcium and higher urine
calcium, other studies did not replicated these findings (16, 22-27). Studies which found different
RS risk factors in PHPT compared to the general population suggest that RS risk profile in PHPT
is unique (21, 24, 27).

Further complicating our understanding, emerging data suggest that serum vitamin D levels may also play a role in RS risk among patients with PHPT (28, 29). Vitamin D deficiency is common in patients with PHPT and maintaining normal vitamin D levels are essential for bone health (30). Vitamin D has been associated with higher risk of RS.(29) Conversely, as vitamin D intake increases calcium absorption, it may exacerbate hypercalcemia and hypercalciuria in some patients, potentially increasing RS risk (28).

Recognizing these knowledge gaps, the latest international PHPT guideline highlights 145 146 "[renal] stone risk" as a research priority, underscoring the need to establish evidence-based risk 147 stratification in this population (13). We therefore aim conduct a systematic review and meta-148 analysis to consolidate and critically appraise the available evidence on the association of six a 149 priori defined risk factors-age, sex, urine calcium, serum calcium, serum PTH and serum 150 vitamin D—with both incident and recurrent RS in PHPT. Although a narrative review in 2011 151 summarized the RS risk factors in PHPT, no systematic review or meta-analysis has been 152 conducted on this topic (21). By integrating data from a broad range of study designs and 153 settings, we aim to provide a clearer understanding of which patients with PHPT are most 154 susceptible to RS development, ultimately informing clinical decision-making.

155 Sub-heading: 2. Objectives

The primary objective of our review is to summarize and meta-analyze the existing evidence on the association of five risk factors (sex, age, serum calcium, urine calcium, and PTH) with both incident (new) or recurrent RS development among adults (\geq 18 years old) with PHPT in outpatient or inpatient settings up to 10 years before or after PHPT diagnosis. For each risk factor, the comparator will be an alternative category of the risk factor. The secondary objective will include evaluating the association of these six risk factors with recurrent RS development.

162 Heading: METHODS

163 Sub-heading: 3. Study Design

164 Our systematic review will be conducted in accordance with the guidelines outlined in the 165 Cochrane Handbook for Systematic Reviews of Interventions (31). This protocol was developed 166 following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 167 2015 checklist (S1. Appendix) (32) and was registered with PROSPERO: an international 168 prospective register of systematic reviews on November 14, 2024 (registration ID: 169 CRD42024608180) (33). Data screening has been completed. Data extraction is estimated to be 170 completed by March-April 2025 and complete results are expected by April-May 2025. The final 171 systematic review will follow the PRISMA-2020 reporting guidelines (34).

172 Sub-heading: 4. Eligibility Criteria and Outcomes

173 Sub-sub-heading Study Type

We will include full-length peer-reviewed prospective cohort, retrospective cohort, case-control, and cross-sectional studies. For cohort studies, the starting point (time 0) will be the diagnosis of PHPT, with follow-up measuring the development of RS. We will not restrict the time duration between PHPT diagnosis and RS development as our primary outcome is RS occurrence irrespective of the time of PHPT diagnosis. Additionally, we will not apply any language,

179 geographic or time restrictions to the search. Google Translate will be used to translate non-180 English studies if necessary (35). Studies will have to report sufficient data to allow for directly 181 or indirectly estimating odds ratios (OR), relative risks (RR), or hazard ratios (HR) with 95% 182 confidence intervals (CIs) for at least one of the predefined risk factors.

We will exclude studies that only include paediatric patients (<18 years old), case series (i.e., those with no quantitative data or fewer than five patients), case reports, commentaries, editorials, non-human studies, review articles, and conference abstracts. Clinical trials will also be excluded to avoid the potential for random allocation obscuring the association between the risk factors and RS (36).

188 **Sub-sub-heading: Participants:** Adults (≥ 18 years old) with symptomatic or asymptotic PHPT 189 will be included. Studies presenting data for both adults and children will only be included if the 190 relevant data are presented separately for adults. The diagnostic criteria for PHPT will be based 191 on internationally recognized standards (13, 37). As most guidelines exclude normocalcemic 192 PHPT in the formal definition of PHPT, we will exclude these patients (13, 37). Studies 193 presenting data on both hypercalcemic and normocalcemic PHPT patients will only be included 194 if the data for these groups are reported separately. We will also exclude data obtained after 195 parathyroidectomy to avoid its confounding effect on RS risk. Studies that include patients who 196 have undergone parathyroidectomy will only be considered if they report relevant data collected 197 before the procedure (12).

Sub-sub-heading: Index prognostic factor: Studies must include at least one of the following
a-priori risk factors: 1- age, 2- sex, 3- urinary calcium, 4- serum calcium, 5- serum PTH, 6-serum
vitamin D.

Sub-sub-heading: Comparator: For each risk factor, the comparator will be patients in an
alternative category of the risk factor.

203 Sub-sub-heading: Outcome: 1) The primary outcome will be incident and recurrent RS 204 development during any time frame relative to PHPT diagnosis. This outcome will provide a 205 comprehensive assessment of RS burden in PHPT, capturing both new and recurrent RS events 206 to characterize the full spectrum of RS. The lack of established risk factors and systematic 207 reviews in this area underscores the need for robust data on the overall risk and natural history of 208 RS in PHPT (15, 38-40). 2) The secondary outcomes will be recurrent RS development. Given 209 that prior RS are a strong predictor of recurrence, clinicians often adopt more intensive 210 management for these patients, including closer monitoring and higher likelihood of 211 parathyroidectomy (39, 41). Focusing on recurrent RS will clarify whether a "one-size-fits-all" 212 approaches to RS risk factors are adequate or if tailored prevention strategies are required for 213 these higher-risk patients. 3) As an **exploratory outcome**, we will assess the mean difference of 214 continuous risk factors between RS and no-RS groups to provide a clinically meaningful 215 interpretation (42, 43). The definition of RS will be based on internationally recognized 216 standards, primarily based on the presence of symptoms or radiographic findings (7, 44, 45).

Sub-sub-heading: Timing: We will assess RS occurrence within a 10-year window before or after PHPT diagnosis as reported in the included studies. This 10-year period is standard in RS risk studies, effectively balancing the capture of relevant clinical outcomes with the minimization of confounding factors (25, 46, 47).

Sub-sub-heading: Setting: Any healthcare (e.g., inpatient, outpatient), geographic (e.g., urban,
rural), and study-specific (e.g., single-centre, population based) will be included.

223 Sub-heading: 5. Information Sources

8

The following online databases will be searched from their inception: Medline (OVID interface, 1946 onwards), Embase (OVID interface, 1947 onwards), and Cochrane Central Register of Controlled Trials (Wiley interface, current issue). References of all eligible articles will be reviewed for additional studies meeting the eligibility criteria (backward citation searching) (48). Databases containing grey literature will not be searched as our focus is on peer-reviewed studies.

230 Sub-heading: 6. Search Strategy

Literature search strategies will be developed using a combination of subject headings (MeSH, EMTREE) and keywords. Database searches will be conducted with the aid of an experienced health information librarian. Two concepts will be included: 1- primary hyperparathyroidism, and 2- RS. These two concepts will then be combined using the "AND" operator to obtain final search results. We will limit the search to only studies involving human subjects and will not apply any language restrictions.

A preliminary search strategy is provided in S2. appendix.

238 Sub-heading: 7. Study Records

239 Sub-sub-heading: 7.a. Data Management

All citations from the literature search will be imported into Covidence and duplicate studies will be removed (49). Following the completion of screening, a PRISMA flow diagram will be generated using Covidence (50).

243 Sub-sub-heading: 7.b. Selection Process

244 Two reviewers will independently screen titles and abstracts of studies uploaded in Covidence,

applying prespecified eligibility criteria. The full texts of studies deemed potentially relevant will

then be independently reviewed for inclusion in the final analysis by the same reviewers.

Reasons for excluding studies will be recorded. Reviewers will resolve disagreements by discussion, and a third reviewer will adjudicate the unresolved disagreements. A calibration exercise involving a small sample of studies (e.g., three) will be conducted before screening begins to ensure consistency and refine eligibility criteria. Reviewers will not be blinded to journal titles, study authors or institutions.

252 Sub-sub-heading; 7.c. Data Extraction

253 For each included study, two reviewers will extract data independently and in duplicates 254 and record the data in standardized data collection tables in Microsoft Excel. These tables will be 255 organized in the recommended PICOTS format for prognostic studies (patient, index prognostic 256 factor, comparator prognostic factor, outcome, time and setting) (51), and will initially be piloted 257 on three studies to allow necessary adjustments for accuracy and completeness. The tables will 258 be created using a modified version of the checklist for critical appraisal and data extraction for 259 systematic reviews of prediction modelling studies for prognostic factors (CHARMS-PF)(52, 260 53). Reviewers will compare the collected data, resolve disagreements by discussion, and a third 261 reviewer will adjudicate the unresolved disagreements.

262 Sub-heading: 8. Data Items

We will record the following data from the included studies where available: 1-Basic study details: first author's last name, publication year, study design, country of origin, sample size, setting, data sources (e.g., self-report, chart review, administrative data), follow-up duration, and loss to follow-up, funding sources. 2- Patient Demographics: age and sex. 3- Biochemical Risk Factors: 24-hour urine calcium, total serum calcium, serum ionized calcium, serum PTH, 25hydroxy vitamin D, and 1-25 dihydroxy vitamin D. Units of measurement for all biochemical variables and the time at which the patient demographics and the biochemical risk factors were

assessed in relation to RS development will be recorded. 4- Clinical History: time of PHPT
diagnosis in relation to RS development, and criteria for PHPT diagnosis. 5- Outcome Measures:
Presence of RS (Specify if RS are incident or recurrent), criteria for RS diagnosis. 6- Other
Relevant Clinical Information: osteoporosis and treatment with calcium supplement (S3.
Appendix).

Whenever available, we will extract adjusted and unadjusted OR, RR, or HR, and their measures of variance. If these measures of association are not available, the relevant descriptive statistics (e.g., mean, median) will be recorded to estimate the unadjusted OR (54, 55). We will also record the variables used to adjust for each risk factor. We will collect data on all *a priori* defined risk factors and outcome-compatible information, regardless of RS definition or timing of RS diagnosis. We will convert data from different studies into consistent units of measurement to ensure uniformity.

282 Sub-sub-heading: Missing Data

In cases of missing or unclear data, authors will be contacted up to two times, allowing two weeks for a response per attempt. If no responses are received regarding essential study eligibility criteria, the study will be excluded (56). Similarly, if essential data required for analysis are not obtained, the study will be excluded from the relevant analysis but will contribute to the descriptive analyses (57).

288 Sub-heading: 9. Quality Appraisal

Two reviewers will independently assess each risk factor's risk of bias using the Quality in Prognostic Studies (QUIPS) tool. Reviewers will resolve disagreements through discussion, and a third reviewer will adjudicate the unresolved disagreements. This tool evaluates six domains: study participation, study attrition, prognostic factor measurement, outcome measurement, study

confounding, and statistical analysis and reporting (58). Each domain will. be rated as high, moderate, or low risk of bias (58). This tool will be initially piloted using three randomly selected studies to confirm consistency across reviewers. A study will be deemed low risk overall if all domains are rated as low risk. Conversely, it will be considered high risk if at least one domain is rated high. Any ratings between these categories will be rated as moderate risk of bias (59, 60). Traffic-light plots will be generated using R- Version 4.4.1.

299 Sub-heading: 10. Data Synthesis

300 We will conduct meta-analyses on all prespecified risk factors and outcomes reported by 301 at least two studies, using the generic inverse variance method within a random-effects model to 302 account for between-study heterogeneity (61, 62). To ensure robust estimation of uncertainty in 303 the overall effect size, the Hartung-Knapp-Sidik-Jonkman adjustment will be applied when at 304 least four studies are included in the meta-analysis (63). When fewer than four studies are 305 available, the Wald method will be used instead (64). The restricted maximum likelihood method 306 will be used to estimate between-study variance (65). Between-study heterogeneity will be 307 assessed by visually inspecting forest plots for overlapping point estimates and CIs, and formally 308 evaluated using the chi-square test and I² statistic (66). Forest plots, summary effect measures 309 with 95% confidence intervals (CIs), and prediction intervals will be generated using R Version 310 4.4.1.

311 Sub-sub-heading: Primary Analysis

We will meta-analyze adjusted risk factors. We will report summary adjusted odds ratios (aORs) with 95% CIs for the association with RS. We will pool all adjusted risk factors regardless of the adjustment variables, without requiring a minimum set of adjustment factors (55). We have chosen this approach for This approach to pooling adjusted effect estimates irrespective of the

12

316 specific covariates is chosen for two primary reasons: 1) The risk factors and confounders for 317 renal stones in PHPT are not well-established(67). Consequently, we expect the included studies 318 to vary widely in the variables they adjust for. Pooling all adjusted estimates allows us to capture 319 at least the effect of partial confounding control (68, 69). 2) Given the lack of established risk 320 factors, our priority is establishing the direction of risk factors with adequate precision. 321 Maximizing the number of studies in the meta-analysis enhances the precision of effect 322 estimates. Previous systematic reviews on prognostic factors have adopted similar approaches 323 (21, 55, 70, 71).

324 Sub-sub-heading: Secondary Analysis

325 We will examine the unadjusted risk factors. For these, we will estimate summary 326 unadjusted odds ratios (uORs) with 95% CIs for the association with RS (72), using the 327 following stepwise approach: 1) **Direct Use of Unadjusted ORs:** If unadjusted ORs are reported 328 by the study, these will be directly used in the meta-analysis. 2) Conversion of Relative 329 Measures: If studies report relative risk (RR) or hazard ratio (HR), HR will equated to RR, and 330 these measures will be converted to OR.(55, 73) 3) Calculating ORs from Regression 331 Coefficients: When regression coefficients are reported without confidence intervals (CI), ORs 332 and their variances will be calculated using the regression coefficients and p-values from logistic 333 or linear regression.(74) If regression coefficients and CIs are reported, ORs will be calculated 334 using the formula: OR= e^beta, where e= 2.718 and β is the regression coefficient (74, 75). 4) 335 Calculating ORs from Cox Regression and Kaplan-Meier Curves: When direct reporting is 336 absent, we will use the number of events and the p-values from reported analyses such as log-337 rank tests or Cox regressions (54, 76). If only Kaplan-Meier curves are reported with no 338 available HR, we will reconstruct the raw time-to-event data from Kaplan-Meier curves and use

339 this data to estimate the HR (77). 5) Deriving ORs from 2x2 Tables: If no measures of 340 association are described but categories of a risk factor in relation to RS are reported, a 2x2 table 341 will be constructed to calculate the OR. 6) Tertile Approach for Continuous Variables: If 342 neither measures of association nor categorical data are available, continuous variables will be 343 analyzed by assuming a normal distribution (55, 78). Using the mean and standard deviation (SD), we will create three groups (tertiles) in R Version 4.4.1 and calculate the OR for the 344 345 highest third versus the lowest third of each prognostic factor (55, 70, 79, 80). When only 346 median and interquartile range (IQR) are reported, these values will be converted to mean and 347 SD (79). If means and SDs are reported per group, data will be combined using the approach 348 suggested in the Cochrane Handbook (81). Studies will be excluded if measures of variance are 349 unavailable (82).

350 To ensure the assumption of normality and avoid unstable tertile conversions, we will 351 apply the following criteria. A study will be included in the tertile analysis if at least two of the 352 following three criteria were met: 1) Minimum number of participants in each group >20 (83). 2) 353 Coefficient of variation (CV) between 0.12 and 0.6 for both groups (84-87). 3) Maximum group 354 size imbalance: ratio of the larger group to the smaller group <4:1 (88). A study will be excluded 355 if any of the following criteria are present: 1) Number of participants in the smallest group $\langle 5, 2 \rangle$ 356 CV <0.1 or >0.95, and 3) Ratio of the larger to the smallest group >20:1. These criteria were 357 derived from the principles outlined in the Cochrane Handbook, relevant methodology papers, 358 and analogous statistical literature to ensure the robustness of the tertile-based calculations (66, 359 81, 87, 89).

360 If a study provides both adjusted and unadjusted effect sizes for a risk factor, we will 361 only use the adjusted effect size in analysis. Additionally, we will report the mean differences 362 between groups with and without RS for each continuous prognostic factor.

363 Sub-sub-heading: Studies with Overlapping Populations

All included studies will be described in the patient characteristics table and their data will be used for descriptive analyses. However, to avoid potential bias and inflation of the statistical significance due to data duplication, only one study from each set of studies with overlapping populations will be included in the meta-analysis. Overlapping populations will be identified based on a careful examination of author information (including affiliations), the time period of patient recruitment, and, if available, details of the study setting (e.g., specific hospitals or clinics). When overlapping populations are identified, we will select the study with the largest

371 sample size, assuming the smaller sample is a subset of the larger study (81, 90, 91).

372 Sub-sub-heading: Biochemical Risk Factors

Serum total calcium and serum ionized calcium will be included in the same unadjusted odds
ratio meta-analysis using the tertile approach. If a study reports both ionized and total calcium,
only ionized calcium will be used, as it is considered a more accurate measure (92). Similarly,
the uOR for 25-hydroxy vitamin D and 1-25 dihydroxy vitamin D will be meta-analyzed together
and 25-hydroxy vitamin D will be prioritized over 1-25 dihydroxy vitamin D if both are
available in a study, as 25-hydroxy vitamin D represents a more accurate measure of body's
vitamin D stores (93-95).

For the analysis of mean differences in biochemical factors between patients with and
without RS, serum total calcium and serum ionized calcium will be analyzed separately.
However, a single certainty of evidence recommendation will be provided for both, as they

15

- 383 represent closely related clinical concepts and because this analysis is exploratory (96). The same
- analytic approach will be employed for mean differences and certainty of evidence reporting for
- 385 25-hydroxy vitamin D and 1-25 dihydroxy vitamin D.

386 Sub-Heading: 11. Subgroup Analyses and Meta-regression

387 Sub-sub-heading: Subgroup Analyses:

- 388 To assess heterogeneity, we will conduct the following subgroup analyses:
- 389 1. By Presence of Osteoporosis: Studies with $\geq 20\%$ will be compared with those with
- 390 <20% of participants having osteoporosis (cutoff chosen based on global prevalence)(97).
- We expect a stronger association between risk factors and RS in patients with
 osteoporosis (98).
- 393 2. By Study Design: Cohort and case-control will be compared with cross-sectional
 394 studies. We expect a stronger association in cross-sectional studies as they tend to have
 395 higher bias (99, 100).
- 396 3. By treatment with thiazide diuretics: within patients treated with thiazide diuretics, we
 397 expect weaker association between the risk factors and RS as thiazide diuretics lower
 398 urinary calcium and potentially RS risk (101).
- 399 Sub-sub-heading: Meta-regression

400 1. By mean serum calcium in each study: We hypothesize that the magnitude of the 401 association between the risk factors and RS will be weaker in studies with higher mean 402 serum calcium levels. This is because, at higher average serum calcium levels within a 403 study population, hypercalcemia is likely to be a more dominant factor in stone 404 formation, potentially overshadowing the influence of other risk factors(102, 103).

405
2. By proportion of females in each study: We hypothesize that the magnitude of the
406
association between other risk factors and RS will be weaker in studies with a smaller
407
difference in the proportion of females between the RS and no-RS groups. This indirect
408
assessment is based on the assumption that a smaller difference in the proportion of
409
females between the groups might reflect a population where sex-related factors play a
410
less prominent role in modifying the influence of other risk factors on renal stone
411
formation (104).

412 Sub-sub-heading: Evaluating the Credibility of Subgroup & Meta-regression Analyses

Two reviewers will independently grade the credibility of each subgroup effect in duplicate using the Instrument for the Credibility of Effect Modification Analyses (ICEMAN) criteria (105). Disagreements will be resolved through discussion between the reviewers and the third reviewer will adjudicate unresolved disagreements. Credibility ratings will be provided assigned as follows: 1- Very Low: all responses are "definitely no" or "probably no. 2- Low: at least two responses are "definitely no." 3-Moderate: one "definitely no" or two "probably no" responses. 4-High: no responses are "definitely no" or "probably no" (106).

420 Sub-heading: 12. Sensitivity Analyses

To confirm the robustness of our findings, we will conduct the following sensitivity analyses: 1) To assess the effect of **consistent covariate selection**, we will only include studies that adjust for at least serum calcium and either age or sex. 2) To examine the influence of **study design**, we will restrict the analysis to cohort and case-control studies, as these designs allow for stronger inferences about associations compared to cross-sectional studies (107). 3) To evaluate the impact of **risk of bias**, we will restrict to studies with low or moderate risk of bias. If a clinically significant difference is found between the primary or secondary analysis and their

428 corresponding sensitivity analyses, we will present the primary analysis and rate down the 429 certainty of evidence.

430 Sub-heading: 13. Reporting Bias

431 For analyses including ≥ 10 studies, we will conduct a primary assessment using funnel plots, the 432 trim-and-fill method, Egger's test for continuous variables, and the Harbord test for dichotomous 433 variables (108-110). To complement these assessments, a secondary assessment will be 434 performed using the Doi plot and Luis Furuya-Kanamori (LFK) index, with values within ± 1 435 interpreted as indicative of no asymmetry (111, 112). In instances where the primary and 436 secondary assessments yielded discrepant results, Begg's test will be employed to provide 437 additional clarification (113, 114). The final determination of publication bias will be based on 438 the consensus of multiple analyses, prioritizing methods with greater sensitivity and reliability 439 for the specific context (110, 115-117). For analyses with < 10 studies, formal assessments of 440 publication bias will not be conducted due to limited statistical power. Instead, publication bias 441 will be considered "unlikely" if small-study effects are improbable, based on the 442 comprehensiveness of the search strategy and expert knowledge (109, 110, 118).

443 Sub-heading: 14. Confidence in Cumulative Evidence

- 444 Two independent reviewers will assess the overall quality of evidence for each risk factor's
- 445 association with the outcomes using the Grading of Recommendations Assessment,
- 446 Development, and Evaluation (GRADE) framework (119). The assessment will be adapted to
- 447 align with GRADE recommendations for prognostic factor studies (120).

448 <u>Sub-heading: 15. Ethics Approval and Consent to Participate</u>

- 449 We plan to conduct a systematic review and meta-analysis which will use data from previously
- 450 published studies and will not collect new data from participants. Therefore, ethics approval and
- 451 consent to participate will not be required.

452 Heading: DISSEMINATION OF INFORMATION

453 Findings will be disseminated through presentations at scientific meetings and published through

454 at least one peer-reviewed manuscript.

455 Heading: DISCUSSION

456 To our knowledge, this is the first systematic review and meta-analysis designed to synthesize 457 and quantify the existing evidence on key risk factors for RS in the setting of PHPT. By 458 addressing the unique demographic and metabolic factors specific to PHPT, this study aims to 459 resolve inconsistencies in the literature and identify PHPT-specific risk factors that may differ 460 from those in the general population. Identifying these risk factors will enable clinicians to more 461 effectively risk-stratify patients with PHPT, facilitating targeted preventive measures, closer 462 monitoring, and timely parathyroidectomy for high-risk individuals. Ultimately, this could 463 reduce the burden of RS, including emergency department visits, renal failure, and associated 464 healthcare costs (4-7, 11, 12).

465 Sub-heading: Limitations

We anticipate that many relevant studies will use a cross-sectional design. While combining
cross-sectional, cohort, and case-control studies in the meta-analysis will enhance precision by
increasing the number of included studies (121), the lack of a temporal component in crosssectional studies will limit our ability to determine whether these risk factors serve as predictors.
To address this limitation, we will conduct sensitivity analyses restricted to cohort and casecontrol studies. Additionally, pooling adjusted estimates that include different covariates will

19

- 472 augment the overall sample size but reduce direct comparability of summary estimates between
- 473 studies and complicate interpretation of effect size magnitude (54, 122, 123). To address these
- 474 limitations, we will conduct sensitivity analyses restricted to studies adjusting for key
- 475 confounders.

476 Heading: AUTHOR CONTRIBUTION

- 477 Conceptualization: Mohammad Jay
- 478 Methodology: Mohammad Jay, Antoine Eskander, Lorraine Lipscombe, Rui Fu
- 479 Project administration: Mohammad Jay, Sorina Andrei
- 480 Supervision: Antoine Eskander, Lorraine Lipscombe
- 481 Validation: Mohammad Jay, Lorraine Lipscombe, Antoine Eskander, Sorina Andrei, Peter
- 482 Hoang, Roland Jones, Hussein Samhat
- 483 Writing original draft: Mohammad Jay
- 484 Writing review & editing: Mohammad Jay, Sorina Andrei, Peter Hoang, Hussein Samhat,
- 485 Roland Jones, Rui Fu, Lorraine Lipscombe, Antoine Eskander

486 Heading: ACKNOWLEDGEMENT

- 487 We extend our gratitude to Dr. Neill Adhikari and Dr. Danny Weisz for their contributions to the
- 488 methodological development of this project. We also sincerely thank Ms. Genevieve Gore for
- 489 her support in developing the draft search strategy.

490 Heading: REFERENCES

- 491 1. Berger C, Almohareb O, Langsetmo L, Hanley DA, Kovacs CS, Josse R, et al.
- 492 Characteristics of hyperparathyroid states in the Canadian multicentre osteoporosis study
- 493 (CaMos) and relationship to skeletal markers. Clin Endocrinol (Oxf). 2015;82(3):359–68.

494	2.	Khan AA, Hanley DA, Rizzoli R, Bollerslev J, Young J, Rejnmark L, et al. Primary
495		hyperparathyroidism: Review and recommendations on evaluation, diagnosis, and
496		management. A Canadian and international consensus. Osteoporos Int. 2017; 28:1-19.
497	3.	Minisola S, Gianotti L, Bhadada SK, Silverberg SJ. Classical complications of primary
498		hyperparathyroidism. Best Pract Res Clin Endocrinol Metab. 2018;32(6):791-803.
499	4.	Lila AR, Sarathi V, Jagtap V, Bandgar T, Menon PS, Shah NS. Renal manifestations of
500		primary hyperparathyroidism. Indian J Endocrinol Metab. 2012;16(2):258-62.
501	5.	Dhondup T, Kittanamongkolchai W, Vaughan LE, Mehta RA, Chhina JK, Enders FT, et al.
502		Risk of ESRD and mortality in kidney and bladder stone formers. Am J Kidney Dis.
503		2018;72(6):790–7.
504	6.	Raheem OA, Khandwala YS, Sur RL, Ghani KR, Denstedt JD. Burden of urolithiasis: Trends
505		in prevalence, treatments, and costs. Eur Urol Focus. 2017;3(1):18-26.
506	7.	Bhojani N, Bjazevic J, Wallace B, Lee L, Kaler KS, Dion M, et al. UPDATE-Canadian
507		Urological Association guideline: Evaluation and medical management of kidney stones. Can
508		Urol Assoc J. 2022;16(6):175.
509	8.	Bilezikian JP, Khan AA, Silverberg SJ, Fuleihan GEH, Marcocci C, Minisola S, et al.
510		Evaluation and Management of Primary Hyperparathyroidism: Summary Statement and
511		Guidelines from the Fifth International Workshop. J Bone Miner Res. 2022;37(11):2293-
512		314.
513	9.	Vescini F, Borretta G, Chiodini I, Boniardi M, Carotti M, Castellano E, et al. Italian
514		guidelines for the management of sporadic primary hyperparathyroidism. Endocr Metab
515		Immune Disord Drug Targets. 2024;24(8):991–1006.

516	10. Miller JA, Gundara J, Harper S, Herath M, Ramchand SK, Farrell S, et al. Primary
517	hyperparathyroidism in adults—(Part II) surgical management and postoperative follow [] up
518	Position statement of the Endocrine Society of Australia, The Australian & New Zealand
519	Endocrine Surgeons, and The Australian & New Zealand Bone and Mineral Society. Clin
520	Endocrinol (Oxf). 2024;101(5):516–30.
521	11. Assadi F, Moghtaderi M. Preventive kidney stones: Continue medical education. Int J Prev
522	Med. 2017;8(1):67.
523	12. Wang X, Shi G, Li G, Tang G. Systematic review of the risk of urolithiasis following
524	parathyroidectomy in patients with primary hyperparathyroidism. Int Urol Nephrol.
525	2024;56(4):1217–25.
526	13. Bilezikian JP, Khan AA, Silverberg SJ, Fuleihan GEH, Marcocci C, Minisola S, et al.
527	Evaluation and management of primary hyperparathyroidism: Summary statement and
528	guidelines from the fifth international workshop. J Bone Miner Res. 2020;37(11):2293–314.
529	14. Singh Ospina NM, Rodriguez-Gutierrez R, Maraka S, Espinosa de Ycaza AE, Jasim S,
530	Castaneda-Guarderas A, et al. Outcomes of parathyroidectomy in patients with primary
531	hyperparathyroidism: A systematic review and meta-analysis. World J Surg. 2016;40:2359-
532	77.
533	15. Bilezikian JP, Cusano NE, Khan AA, Liu J-M, Marcocci C, Bandeira F. Primary
534	hyperparathyroidism. Nat Rev Dis Primers. 2016;2(1):1–16. https://doi.org/10.xxxx.
535	16. Corbetta S, Baccarelli A, Aroldi A, Vicentini L, Fogazzi G, Eller-Vainicher C, et al. Risk
536	factors associated with kidney stones in primary hyperparathyroidism. J Endocrinol Invest.
537	2005;28:122-8.

- 538 17. Islam AK, Holt S, Reisch J, Nwariaku F, Antonelli J, Maalouf NM. What predicts recurrent
- 539 kidney stone after parathyroidectomy in patients with primary hyperparathyroidism? J Am
- 540 Coll Surg. 2020;231(1):74–82.
- 541 18. Wang K, Ge J, Han W, Wang D, Zhao Y, Shen Y, et al. Risk factors for kidney stone disease
- recurrence: A comprehensive meta-analysis. BMC Urol. 2022;22(1):62.
- 543 19. Ali Z, Rustandi R, Sulchan M, Birowo P, Winarni TI. Comparing the risk factors of
- nephrolithiasis in Asian countries population: A systematic review and meta-analysis. Arab J
 Urol. 2024;22(2):109–14.
- 546 20. Saponaro F, Cetani F, Mazoni L, Apicella M, Di Giulio M, Carlucci F, et al. Hypercalciuria:
- 547 its value as a predictive risk factor for nephrolithiasis in asymptomatic primary

548 hyperparathyroidism? J Endocrinol Invest. 2020;43:677–82.

- 549 21. Rejnmark L, Vestergaard P, Mosekilde L. Nephrolithiasis and renal calcifications in primary
 550 hyperparathyroidism. J Clin Endocrinol Metab. 2011;96(8):2377–85.
- 551 22. Silverberg SJ, Shane E, Jacobs TP, Siris ES, Gartenberg F, Seldin D, et al. Nephrolithiasis
- and bone involvement in primary hyperparathyroidism. Am J Med. 1990;89(3):327–34.
- 553 23. Mollerup CL, Lindewald H. Renal stones and primary hyperparathyroidism: Natural history
- of renal stone disease after successful parathyroidectomy. World J Surg. 1999;23(2):173.
- 555 24. Frøkjaer VG, Mollerup CL. Primary hyperparathyroidism: Renal calcium excretion in
- patients with and without renal stone disease before and after parathyroidectomy. World J
- 557 Surg. 2002; 26:532–5.
- 558 25. Berger AD, Wu W, Eisner BH, Cooperberg MR, Duh Q-Y, Stoller ML. Patients with
- primary hyperparathyroidism—why do some form stones? J Urol. 2009;181(5):2141–5.

- 560 26. D'Angelo A, Lodetti M, Giannini S, Castrignano R, al Awady M, Malvasi L, et al.
- 561 Hyperparathyroidism: Cause or consequence of recurrent calcium nephrolithiasis? Miner
- 562 Electrolyte Metab. 1992;18(6):359–64.
- 563 27. Odvina CV, Sakhaee K, Heller HJ, Peterson RD, Poindexter JR, Padalino PK, et al.
- 564 Biochemical characterization of primary hyperparathyroidism with and without kidney
- 565 stones. Urol Res. 2007; 35:123–8.
- 566 28. Broadus A, Horst R, Lang R, Littledike E, Rasmussen H. The importance of circulating 1,25-
- 567 dihydroxyvitamin D in the pathogenesis of hypercalciuria and renal-stone formation in
- 568 primary hyperparathyroidism. N Engl J Med. 1980;302(8):421–6.
- 569 29. Castellano E, Attanasio R, Latina A, Visconti G, Cassibba S, Borretta G. Nephrolithiasis in
- 570 primary hyperparathyroidism: A comparison between silent and symptomatic patients.
- 571 Endocr Pract. 2017;23(2):157–62.
- 572 30. Walker M, Cong E, Lee J, Kepley A, Zhang C, McMahon D, et al. Vitamin D in primary
- 573 hyperparathyroidism: Effects on clinical, biochemical, and densitometric presentation. J Clin
- 574 Endocrinol Metab. 2015;100(9):3443–51.
- 575 31. Chandler J, Cumpston M, Li T, Page MJ, Welch V. Cochrane handbook for systematic
 576 reviews of interventions. Hoboken: Wiley; 2019.
- 577 32. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred
- 578 reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015
- 579 statement. Syst Rev. 2015; 4:1–9.
- 580 33. Booth A, Clarke M, Dooley G, Ghersi D, Moher D, Petticrew M, et al. The nuts and bolts of
- 581 PROSPERO: an international prospective register of systematic reviews. Syst Rev. 2012;
- 582 1:1–9.

- 583 34. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. Updating
- 584 guidance for reporting systematic reviews: development of the PRISMA 2020 statement. J
- 585 Clin Epidemiol. 2021; 134:103–12.
- 586 35. Jackson JL, Kuriyama A, Anton A, Choi A, Fournier J-P, Geier A-K, et al. The accuracy of
- 587 Google Translate for abstracting data from non–English-language trials for systematic
- 588 reviews. Ann Intern Med. 2019;171(9):677–9.
- 589 36. Valentine JC, Thompson SG. Issues relating to confounding and meta analysis when
- including non randomized studies in systematic reviews on the effects of interventions. Res
- 591 Synth Methods. 2013;4(1):26–35.
- 592 37. Wilhelm SM, Wang TS, Ruan DT, Lee JA, Asa SL, Duh Q-Y, et al. The American
- 593 Association of Endocrine Surgeons guidelines for definitive management of primary
- 594 hyperparathyroidism. JAMA Surg. 2016;151(10):959–68.
- 595 38. Pallan S, Rahman MO, Khan AA. Diagnosis and management of primary
- 596 hyperparathyroidism. BMJ. 2012;344.
- 597 39. Charles P-Y, Letavernier E, Périé S, Gauthé M, Daudon M, Haymann J. Effect of
- 598 parathyroidectomy on renal stone recurrence. Urolithiasis. 2021; 49:327–34.
- 599 40. Sant V, Elnakieb Y, Lehmann C, Rousseau J, Maalouf N. Patient characteristics,
- 600 management, and outcomes in a novel cohort of primary hyperparathyroidism. J Endocr Soc.601 2024:8.
- 602 41. Chandler J, Cumpston M, Li T, Page MJ, Welch V. Cochrane handbook for systematic
- 603 reviews of interventions. Hoboken: Wiley; 2019.

- 42. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred
- reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015
- 606 statement. Syst Rev. 2015; 4:1–9.
- 43. Booth A, Clarke M, Dooley G, Ghersi D, Moher D, Petticrew M, et al. The nuts and bolts of
- 608 PROSPERO: an international prospective register of systematic reviews. Syst Rev. 2012;
- 609 1:1–9.
- 610 44. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. Updating
- 611 guidance for reporting systematic reviews: development of the PRISMA 2020 statement. J
- 612 Clin Epidemiol. 2021; 134:103–12.
- 613 45. Jackson JL, Kuriyama A, Anton A, Choi A, Fournier J-P, Geier A-K, et al. The accuracy of
- 614 Google Translate for abstracting data from non–English-language trials for systematic
- 615 reviews. Ann Intern Med. 2019;171(9):677–9.
- 616 46. Valentine JC, Thompson SG. Issues relating to confounding and meta analysis when
- 617 including non randomized studies in systematic reviews on the effects of interventions. Res
- 618 Synth Methods. 2013;4(1):26–35.
- 619 47. Wilhelm SM, Wang TS, Ruan DT, Lee JA, Asa SL, Duh Q-Y, et al. The American
- 620 Association of Endocrine Surgeons guidelines for definitive management of primary
- 621 hyperparathyroidism. JAMA Surg. 2016;151(10):959–68.
- 48. Pallan S, Rahman MO, Khan AA. Diagnosis and management of primary
- hyperparathyroidism. BMJ. 2012;344.
- 624 49. Charles P-Y, Letavernier E, Périé S, Gauthé M, Daudon M, Haymann J. Effect of
- 625 parathyroidectomy on renal stone recurrence. Urolithiasis. 2021; 49:327–34.

- 626 50. Sant V, Elnakieb Y, Lehmann C, Rousseau J, Maalouf N. Patient characteristics,
- management, and outcomes in a novel cohort of primary hyperparathyroidism. J Endocr Soc.2024:8.
- 629 51. Zhou Y, Chu X, Jiang D, Wu X, Xu J, Qi H, et al. Development and validation of a
- 630 nomogram for risk prediction of nephrolithiasis recurrence in patients with primary
- 631 hyperparathyroidism. Front Endocrinol. 2022;13.
- 632 52. Johnston B, Patrick D, Thorlund K, Busse J, Da Costa B, Schünemann H, et al. Patient-
- 633 reported outcomes in meta-analyses: Part 2: methods for improving interpretability for
- decision-makers. Health Qual Life Outcomes. 2013; 11:211.
- 635 53. Takeshima N, Sozu T, Tajika A, Ogawa Y, Hayasaka Y, Furukawa T. Which is more
- generalizable, powerful and interpretable in meta-analyses: mean difference or standardized
 mean difference? BMC Med Res Methodol. 2014; 14:30.
- 638 54. Zeng G, Zhao Z, Mazzon G, Pearle M, Choong S, Skolarikos A, et al. European association
- of urology section of urolithiasis and international alliance of urolithiasis joint consensus on
- retrograde intrarenal surgery for the management of renal stones. Eur Urol Focus.
- 641 2022;8(5):1461–8.
- 55. Taran S, Angeloni N, Pinto R, Lee S, McCredie VA, Schultz MJ, et al. Prognostic factors

associated with extubation failure in acutely brain-injured patients: a systematic review and
meta-analysis. Crit Care Med. 2023;51(3):401–12.

- 56. Godolphin P, Bath P, Montgomery A. Short email with attachment versus long email without
- attachment when contacting authors to request unpublished data for a systematic review: a
- 647 nested randomised trial. BMJ Open. 2019;9.

- 648 57. Mavridis D, White IR. Dealing with missing outcome data in meta□analysis. Res Synth
 649 Methods. 2020;11(1):2–13.
- 650 58. Hayden J, Van Der Windt D, Cartwright J, Côté P, Bombardier C. Assessing Bias in Studies
- of Prognostic Factors. Ann Intern Med. 2013; 158:280–6.
- 59. Grooten W, Tseli E, Äng B, Boersma K, Stålnacke B, Gerdle B, et al. Elaborating on the
- assessment of the risk of bias in prognostic studies in pain rehabilitation using QUIPS—
- aspects of interrater agreement. Diagn Progn Res. 2019;3.
- 655 60. Viswanathan M, Patnode C, Berkman N, Bass E, Chang S, Hartling L, et al.
- 656 Recommendations for assessing the risk of bias in systematic reviews of health-care
- interventions. J Clin Epidemiol. 2017; 97:26–34.
- 658 61. Cheung MWL, Cheung SF. Random effects models for meta analytic structural equation
 659 modeling: review, issues, and illustrations. Res Synth Methods. 2016;7(2):140–55.
- 660 62. Borenstein M, Hedges L, Rothstein H. Meta-analysis: Fixed effect vs. random effects. Meta661 Analysis Com. 2007:1–162.
- 662 63. Röver C, Knapp G, Friede T. Hartung-Knapp-Sidik-Jonkman approach and its modification
- for random-effects meta-analysis with few studies. BMC Med Res Methodol. 2015; 15:1–7.
- 664 64. Wu J, Jiang G. Confidence intervals of effect size for paired studies. Biometrical J. 2007;49.
- 665 65. Veroniki AA, Jackson D, Viechtbauer W, Bender R, Bowden J, Knapp G, et al. Methods to
- estimate the between \Box study variance and its uncertainty in meta \Box analysis. Res Synth
- 667 Methods. 2016;7(1):55–79.
- 668 66. Deeks JJ, Higgins JP, Altman DG, Group CSM. Analysing data and undertaking
- 669 meta analyses. Cochrane Handbook for Systematic Reviews of Interventions. 2019:241–84.

670	67. Rejnmark L, Vestergaard P, Mosekilde L. Nephrolithiasis and renal calcifications in primary
671	hyperparathyroidism. J Clin Endocrinol Metab. 2011;96(8):2377–85.

- 672 68. Yan R, Liu T, Peng Y, Peng X. Can statistical adjustment guided by causal inference
- 673 improve the accuracy of effect estimation? A simulation and empirical research based on
- 674 meta-analyses of case–control studies. BMC Med Inform Decis Mak. 2020.
- 675 69. Hamra G, Lesko C, Buckley J, Jensen E, Tancredi D, Lau B, et al. Combining effect
- 676 estimates across cohorts and sufficient adjustment sets for collaborative research.
- 677 Epidemiology. 2021; 32:421–4.
- 678 70. Hemingway H, Philipson P, Chen R, Fitzpatrick NK, Damant J, Shipley M, et al. Evaluating
- the quality of research into a single prognostic biomarker: a systematic review and meta-
- analysis of 83 studies of C-reactive protein in stable coronary artery disease. PLoS Med.
- 681 2010;7(6):e1000286.
- 682 71. Riley RD, Elia EG, Malin G, Hemming K, Price MP. Multivariate meta-analysis of
- prognostic factor studies with multiple cut-points and/or methods of measurement. Stat Med.
- 684 2015;34(17):2481–96.
- 685 72. Schroeder K, Jia H, Smaldone A. Which propensity score method best reduces confounder
- 686 imbalance? An example from a retrospective evaluation of a childhood obesity intervention.
- 687 Nurs Res. 2016;65(6):465–74.
- 688 73. Bertic M, Worme M, Foroutan F, Rao V, Ross H, Billia F, et al. Predictors of survival and
- favorable neurologic outcome in patients treated with eCPR: a systematic review and meta-
- analysis. J Cardiovasc Transl Res. 2022;15(2):279–90.
- 691 74. Sroka C, Nagaraja H. Odds ratios from logistic, geometric, Poisson, and negative binomial
 692 regression models. BMC Med Res Methodol. 2018;18.

- 693 75. Bouyer J. [Logistic regression and epidemiology. I]. Rev Epidemiol Sante Publique.
- 694 1991;39(1):79–87.
- 695 76. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating
- summary time-to-event data into meta-analysis. Trials. 2007; 8:1–16.
- 697 77. Fu R, Sekercioglu N, Mathur MB, Couban R, Coyte PC. Dialysis initiation and all-cause
- 698 mortality among incident adult patients with advanced CKD: a meta-analysis with bias
- 699 analysis. Kidney Med. 2021;3(1):64–75. e1.
- 700 78. Agresti A. Applying R²-type measures to ordered categorical data. Technometrics. 1986;
- 701 28:133–8.
- 702 79. Wan X, Wang W-C, Liu J, Tong T. Estimating the sample mean and standard deviation from
- the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014;14.
- 704 80. Kulldorff M, Sinha R, Chow W, Rothman N. Comparing odds ratios for nested subsets of

705 dietary components. Int J Epidemiol. 2000;29(6):1060–4.

- 706 81. Higgins JP, Li T, Deeks JJ. Choosing effect measures and computing estimates of effect.
- 707 Cochrane Handbook for Systematic Reviews of Interventions. 2019:143–76.
- 82. Longford N. Unreported standard errors in meta-analysis. Stat Transit New Ser. 2021; 22:1–
 17.
- 83. Lin L. Bias caused by sampling error in meta-analysis with small sample sizes. PLoS One.
 2018;13(9): e0204056.
- 712 84. Krishnamoorthy K, Lee M. Improved tests for the equality of normal coefficients of
- 713 variation. Comput Stat. 2014; 29:215–32.

714	85. Eldridge	SM. A	Ashbv D	. Kerry	S. Sam	ple size	for cluster	[•] randomized	trials: effect	ct of
, <u> </u> .	001 210110 20	~, _	10110 / 2	,,			101 010000	100100000000000000000000000000000000000		

- 715 coefficient of variation of cluster size and analysis method. Int J Epidemiol.
- 716 2006;35(5):1292–300.
- 717 86. Viechtbauer W, Nakagawa S. Revisiting and expanding the meta-analysis of variation: The
- 718 log coefficient of variation ratio, lnCVR. bioRxiv. 2020.
- 719 87. Harwell M. An effect size for variance heterogeneity in meta-analysis. Commun Stat Simul
 720 Comput. 2019; 50:1955–70.
- 721 88. Alamolhoda M, Ayatollahi SMT, Bagheri Z. A comparative study of the impacts of
- unbalanced sample sizes on the four synthesized methods of meta-analytic structural
- requation modeling. BMC Res Notes. 2017;10(1):446.
- 89. Eldridge S, Ashby D, Kerry S. Sample size for cluster randomized trials: effect of coefficient
- of variation of cluster size and analysis method. Int J Epidemiol. 2006;35(5):1292–300.
- 726 90. Lefebvre C, Glanville J, Briscoe S, Littlewood A, Marshall C, Metzendorf MI, et al.
- 727 Searching for and selecting studies. Cochrane Handbook for Systematic Reviews of
- 728 Interventions. 2019:67–107.
- 91. Bom PR, Rachinger H. A generalized weights solution to sample overlap in meta analysis.
 Res Synth Methods. 2020;11(6):812–32.
- 731 92. Schenck PA, Chew DJ. Calcium: total or ionized? Vet Clin North Am Small Anim Pract.
- 732 2008;38(3):497–502.
- 733 93. Souberbielle J-C, Body J-J, Lappe JM, Plebani M, Shoenfeld Y, Wang TJ, et al. Vitamin D
- and musculoskeletal health, cardiovascular disease, autoimmunity and cancer:
- Recommendations for clinical practice. Autoimmun Rev. 2010;9(11):709–15.

736	94. Bouillon R, Norman AW, Lips P. Vitamin D deficiency. N Engl J Med. 2007;357(19):1980–
737	1.
738	95. Hollis BW. Circulating 25-hydroxyvitamin D levels indicative of vitamin D sufficiency:
739	implications for establishing a new effective dietary intake recommendation for vitamin D. J
740	Nutr. 2005;135(2):317–22.
741	96. Hultcrantz M, Rind D, Akl E, Treweek S, Mustafa R, Iorio A, et al. The GRADE Working
742	Group clarifies the construct of certainty of evidence. J Clin Epidemiol. 2017; 87:4–13.
743	97. Salari N, Ghasemi H, Mohammadi L, Behzadi Mh, Rabieenia E, Shohaimi S, et al. The
744	global prevalence of osteoporosis in the world: a comprehensive systematic review and meta-
745	analysis. J Orthop Surg Res. 2021;16(1):609.
746	98. Giannini S, Nobile M, Dalle Carbonare L, Lodetti MG, Sella S, Vittadello G, et al.
747	Hypercalciuria is a common and important finding in postmenopausal women with
748	osteoporosis. Eur J Endocrinol. 2003;149(3):209–13.
749	99. Shahar E, Shahar D. Causal diagrams and the cross-sectional study. Clin Epidemiol. 2013;
750	5:57–65.
751	100. Desrosiers J, Hebert R, Bravo G, Rochette A. Comparison of cross-sectional and longitudinal
752	designs in the study of aging of upper extremity performance. J Gerontol A Biol Sci Med Sci.
753	1998;53(5):B362–8.

- 754 101. Cunha TdS, Gomes SA, Heilberg IP. Thiazide and thiazide-like diuretics in nephrolithiasis.
 755 Braz J Nephrol. 2020;43(1):103–9.
- 756 102. Goltzman D. Pathophysiology of hypercalcemia. Endocrinol Metab Clin. 2021;50(4):591–
 757 607.

758	103. Lumachi F.	Motta R.	Cecchin D.	Ave S.	Camozzi V	MM Basso S.	et al. Calcium
150	105. Damacin I	, ITTOILLIN,					, ot un outorun

- metabolism & hypercalcemia in adults. Curr Med Chem. 2011;18(23):3529–36.
- 760 104. Dadon T, Tsvetov G, Levi S, Gorshtein A, Slutzky-Shraga I, Hirsch D. Gender differences in
- the presentation, course and outcomes of primary hyperparathyroidism. Maturitas. 2021;
- 762 145:12–7.
- 763 105.Hayward RA, Gagnier JJ, Borenstein M, VanDerHeijden GJ, Dahabreh IJ, Sun X, et al.
- 764 Instrument for the Credibility of Effect Modification Analyses (ICEMAN) in randomized
- controlled trials and meta-analyses: manual Version 1.0.
- 106. Ademola A, Thabane L, Adekanye J, Okikiolu A, Babatunde S, Almekhlafi MA, et al. The
- 767 credibility of subgroup analyses reported in stroke trials is low: A systematic review. Int J
 768 Stroke. 2023;18(10):1161–8.
- 107. Mann C. Observational research methods. Research design II: cohort, cross-sectional, and
 case-control studies. Emerg Med J. 2003; 20:54–60.
- 108. Sterne JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, Lau J, et al. Recommendations for
- examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlledtrials. BMJ. 2011;343.
- 109. Page MJ, Higgins JP, Sterne JA. Assessing risk of bias due to missing results in a synthesis.

775 Cochrane Handbook for Systematic Reviews of Interventions. 2019:349–74.

- 110. Borenstein M, Hedges LV, Higgins JP, Rothstein HR. Introduction to meta-analysis.
- Hoboken: John Wiley & Sons; 2021.
- 111. Furuya-Kanamori L, Barendregt JJ, Doi SA. A new improved graphical and quantitative
- method for detecting bias in meta-analysis. JBI Evid Implement. 2018;16(4):195–203.

- 780 112. Doi SA. Rendering the Doi plot properly in meta-analysis. JBI Evid Implement.
- 781 2018;16(4):242–3.
- 113. Van Enst WA, Ochodo E, Scholten RJ, Hooft L, Leeflang MM. Investigation of publication
- bias in meta-analyses of diagnostic test accuracy: a meta-epidemiological study. BMC Med
- 784 Res Methodol. 2014; 14:1–11.
- 114. Michael H. The power functions of Begg's and Egger's tests for publication bias. Stat Neerl.
 2024.
- 115. Mathur M, VanderWeele T. Sensitivity analysis for publication bias in meta□ analyses. J R
 Stat Soc Ser C Appl Stat. 2019; 69:1091–119.
- 116. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple,
 graphical test. BMJ. 1997;315(7109):629–34.
- 117. Fajar J. Approaches for identifying and managing publication bias in meta-analysis. DekaMed. 2024.
- 118. Guyatt G, Oxman A, Montori V, Vist G, Kunz R, Brożek J, et al. GRADE guidelines: 5.
- Rating the quality of evidence--publication bias. J Clin Epidemiol. 2011;64(12):1277–82.
- 795 119. Shao S-C, Kuo L-T, Huang Y-T, Lai P-C, Chi C-C. Using Grading of Recommendations
- Assessment, Development, and Evaluation (GRADE) to rate the certainty of evidence of
- study outcomes from systematic reviews: a quick tutorial. Dermatol Sin. 2023;41(1):3–7.
- 120. Foroutan F, Guyatt G, Zuk V, Vandvik P, Alba A, Mustafa R, et al. Use of GRADE for
- assessment of evidence about prognostic factors: rating certainty in identification of groups
- 800 of patients with different absolute risks. J Clin Epidemiol. 2020.
- 801 121. Quintana DS. A guide for calculating study-level statistical power for meta-analyses. Adv
- 802 Methods Pract Psychol Sci. 2023;6(1):25152459221147260.

- 803 122. Ding Y. Risk adjustment: towards achieving meaningful comparison of health outcomes in
- the real world. Ann Acad Med Singap. 2009;38(6):552–7.
- 805 123. Groenwold R, Hak E, Hoes A. Pooling of confounders did not induce residual confounding
- in influenza vaccination studies. Ann Epidemiol. 2009;19(6):432–6.
- 807
- 808
- 809
- 810
- 010
- 811
- ~ •
- 812
- 813
- 814
- 815
- 816 Heading: SUPPORTING INFORMATION
- 817 <u>Sub-heading: S1. Appendix:</u> Preferred Reporting Items for Systematic review and Meta-
- 818 Analysis Protocols 2015 checklist
- 819
- 820 <u>Subheading: S2. Appendix</u>: Draft search strategy
 821
- 822 <u>Subheading: S3. Appendix:</u> Variables for Data Extraction
- 823